{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:11:55Z","timestamp":1790737915299,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jpsychires.2016.05.013","type":"journal-article","created":{"date-parts":[[2016,5,29]],"date-time":"2016-05-29T07:13:19Z","timestamp":1464505999000},"page":"14-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Could cannabidiol be used as an alternative to antipsychotics?"],"prefix":"10.1016","volume":"80","author":[{"given":"Marc","family":"Fakhoury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2016.05.013_bib1","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pharmthera.2006.08.004","article-title":"Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission","volume":"113","author":"Alex","year":"2007","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib2","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pnpbp.2012.10.024","article-title":"Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test","volume":"41","author":"Almeida","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib3","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0140-6736(87)92620-1","article-title":"Cannabis and schizophrenia. A longitudinal study of Swedish conscripts","volume":"2","author":"Andreasson","year":"1987","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib4","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/bmj.325.7374.1212","article-title":"Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study","volume":"325","author":"Arseneault","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0893-133X(01)00230-5","article-title":"Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release","volume":"25","author":"Balla","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/157015907780866910","article-title":"Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity","volume":"5","author":"Basavarajappa","year":"2007","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157488611798280924","article-title":"Safety and side effects of cannabidiol, a Cannabis sativa constituent","volume":"6","author":"Bergamaschi","year":"2011","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib8","doi-asserted-by":"crossref","first-page":"15248","DOI":"10.1073\/pnas.0606578103","article-title":"Activation, internalization, and recycling of the serotonin 2A receptor by dopamine","volume":"103","author":"Bhattacharyya","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib10","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/bmb\/ldh007","article-title":"Migration, distress and cultural identity","volume":"69","author":"Bhugra","year":"2004","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib11","first-page":"18","article-title":"Migration, cultural bereavement and cultural identity","volume":"4","author":"Bhugra","year":"2005","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib12","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.chembiol.2007.11.006","article-title":"A\u00a0comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol","volume":"14","author":"Blankman","year":"2007","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib13","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1007\/s00213-015-3915-0","article-title":"Further human evidence for striatal dopamine release induced by administration of 9-tetrahydrocannabinol (THC): selectivity to limbic striatum","volume":"232","author":"Bossong","year":"2015","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/npp.2008.138","article-title":"Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum","volume":"34","author":"Bossong","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib15","first-page":"47","article-title":"The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue","volume":"5","author":"Brisch","year":"2014","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.31887\/DCNS.2004.6.1\/acaspi","article-title":"Treatment-refractory schizophrenia","volume":"6","author":"Caspi","year":"2004","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib17","first-page":"252","article-title":"The therapeutic role of 5-HT1A and 5-HT2A receptors in depression","volume":"29","author":"Celada","year":"2004","journal-title":"J.\u00a0Psychiatry Neurosci."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib18","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.109.066217","article-title":"Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis","volume":"196","author":"Crossley","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib19","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/sj.npp.1300496","article-title":"The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis","volume":"29","author":"D\u2019Souza","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib20","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.biopsych.2004.12.006","article-title":"Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction","volume":"57","author":"D\u2019Souza","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib21","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/npp.2011.43","article-title":"Paranoid schizophrenia is characterized by increased CB1 receptor binding in the dorsolateral prefrontal cortex","volume":"36","author":"Dalton","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-511X-2-5","article-title":"Endocannabinoid signalling in the blood of patients with schizophrenia","volume":"2","author":"De Marchi","year":"2003","journal-title":"Lipids Health Dis."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.jpsychires.2016.05.013_bib23","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1055\/s-2007-992133","article-title":"Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action","volume":"40","author":"Di Pietro","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib24","first-page":"CD009831","article-title":"Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders","volume":"1","author":"Dold","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib25","first-page":"122","article-title":"Withdrawal from clozapine: the \u201crebound phenomenon\u201d","volume":"36","author":"Durst","year":"1999","journal-title":"Isr. J. Psychiatry Relat. Sci."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib26","first-page":"1","article-title":"Role of the endocannabinoid system in the pathophysiology of schizophrenia","author":"Fakhoury","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1017\/S0033291702006402","article-title":"Cannabis dependence and psychotic symptoms in young people","volume":"33","author":"Fergusson","year":"2003","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s002130100811","article-title":"Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review","volume":"156","author":"Geyer","year":"2001","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib29","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/npp.2011.76","article-title":"A\u00a0novel alpha5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia","volume":"36","author":"Gill","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-25761-2_2","article-title":"Role of dopamine D(2) receptors for antipsychotic activity","author":"Ginovart","year":"2012","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib31","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/npp.2012.91","article-title":"Chronic Delta(9)-tetrahydrocannabinol exposure induces a sensitization of dopamine D(2)\/(3) receptors in the mesoaccumbens and nigrostriatal systems","volume":"37","author":"Ginovart","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib32","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1038\/sj.npp.1300558","article-title":"Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms","volume":"29","author":"Giuffrida","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib33","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00213-010-2036-z","article-title":"The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors","volume":"213","author":"Gomes","year":"2011","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s002130050901","article-title":"Clozapine as a drug of dependence","volume":"142","author":"Goudie","year":"1999","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1017\/S1461145710000209","article-title":"Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine","volume":"14","author":"Guidali","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbr.2011.03.053","article-title":"Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia","volume":"222","author":"Gururajan","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1590\/S1516-44462010000100011","article-title":"Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)","volume":"32","author":"Hallak","year":"2010","journal-title":"Rev. Bras. Psiquiatr."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib38","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2013the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.schres.2015.01.033","article-title":"A\u00a0systematic review of the antipsychotic properties of cannabidiol in humans","volume":"162","author":"Iseger","year":"2015","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.schres.2012.07.021","article-title":"Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia","volume":"141","author":"Jenko","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib41","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib42","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0006-3223(00)00976-8","article-title":"Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia","volume":"48","author":"Kegeles","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib43","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1192\/bjp.bp.108.053843","article-title":"Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis","volume":"194","author":"Koethe","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1574889809666140307115532","article-title":"Therapeutic potential of cannabinoids in schizophrenia","volume":"9","author":"Kucerova","year":"2014","journal-title":"Recent Pat. CNS Drug Discov."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2012.11.041","article-title":"Modafinil disrupts prepulse inhibition in mice: strain differences and involvement of dopaminergic and serotonergic activation","volume":"699","author":"Kwek","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib46","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/JCP.0b013e3182114d21","article-title":"Differential 3-year effects of first- versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models","volume":"31","author":"Lambert","year":"2011","journal-title":"J.\u00a0Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib47","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4088\/PCC.v02n0601","article-title":"Atypical antipsychotic use in the treatment of psychosis in primary care","volume":"2","author":"Leo","year":"2000","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib48","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/00001756-199906030-00008","article-title":"Elevated endogenous cannabinoids in schizophrenia","volume":"10","author":"Leweke","year":"1999","journal-title":"Neuroreport"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib49","article-title":"The efficacy of cannabidiol in the treatment of schizophrenia - a translational approach","volume":"37","author":"Leweke","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib50","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2007.04.025","article-title":"Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use","volume":"94","author":"Leweke","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib52","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.neubiorev.2009.02.001","article-title":"Top-down modulation of prepulse inhibition of the startle reflex in humans and rats","volume":"33","author":"Li","year":"2009","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib54","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbr.2009.01.031","article-title":"Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia","volume":"204","author":"Lodge","year":"2009","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib55","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.npp.1300838","article-title":"Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice","volume":"31","author":"Long","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib56","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1017\/S1461145709990605","article-title":"A\u00a0behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL\/6JArc mice","volume":"13","author":"Long","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib57","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/08039480801959307","article-title":"Negative symptoms in schizophrenia: a review","volume":"62","author":"Makinen","year":"2008","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib58","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pbb.2009.04.010","article-title":"Cannabidiol reverses the reduction in social interaction produced by low dose Delta(9)-tetrahydrocannabinol in rats","volume":"93","author":"Malone","year":"2009","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib59","first-page":"36","article-title":"Antipsychotic-induced movement disorders: evaluation and treatment","volume":"2","author":"Mathews","year":"2005","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib61","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/157015909790031229","article-title":"Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: part I","volume":"7","author":"Miller","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib62","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.bbi.2012.12.011","article-title":"Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine","volume":"30","author":"Moller","year":"2013","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1600-0447.2006.00787.x","article-title":"Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse","volume":"114","author":"Moncrieff","year":"2006","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib64","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejphar.2005.02.040","article-title":"Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice","volume":"512","author":"Moreira","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-244X-8-32","article-title":"Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia","volume":"8","author":"Morken","year":"2008","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.schres.2013.06.013","article-title":"Quantification of endocannabinoids in postmortem brain of schizophrenic subjects","volume":"148","author":"Muguruza","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib67","first-page":"137","article-title":"Neurodevelopmental impairment, dopamine sensitisation, and social adversity in schizophrenia","volume":"1","author":"Murray","year":"2002","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib68","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00221-006-0503-x","article-title":"Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia","volume":"172","author":"Newell","year":"2006","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib69","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3389\/fpsyt.2013.00130","article-title":"Does cannabidiol protect against adverse psychological effects of THC?","volume":"4","author":"Niesink","year":"2013","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib71","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrn4004","article-title":"Endocannabinoid signalling in reward and addiction","volume":"16","author":"Parsons","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib72","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel","year":"2014","journal-title":"Pharm Ther."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib73","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1017\/S1461145712001344","article-title":"Hippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia","volume":"16","author":"Perez","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib74","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib75","first-page":"51","article-title":"FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels","volume":"11","author":"Petrosino","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib76","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neubiorev.2005.04.016","article-title":"The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?","volume":"30","author":"Pierce","year":"2006","journal-title":"Neurosci. Biobehav Rev."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib77","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4103\/0019-5545.58304","article-title":"The story of antipsychotics: past and present","volume":"51","author":"Ramachandraiah","year":"2009","journal-title":"Indian J. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib78","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0079-6123(08)00906-0","article-title":"Alterations of dopamine and serotonin transmission in schizophrenia","volume":"172","author":"Remington","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib79","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.euroneuro.2013.11.002","article-title":"Cannabidiol as a potential treatment for psychosis","volume":"24","author":"Schubart","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib80","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1755-5949.2010.00162.x","article-title":"All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors","volume":"17","author":"Seeman","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib81","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1126\/science.1145194","article-title":"Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons","volume":"188","author":"Seeman","year":"1975","journal-title":"Science"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib82","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1073\/pnas.0409766102","article-title":"Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis","volume":"102","author":"Seeman","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib83","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/npp.2013.81","article-title":"Phencyclidine-induced social withdrawal results from deficient stimulation of cannabinoid CB(1) receptors: implications for schizophrenia","volume":"38","author":"Seillier","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib84","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1017\/S146114570999023X","article-title":"Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats","volume":"13","author":"Seillier","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib85","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3758\/s13415-013-0211-5","article-title":"Common and specific cognitive deficits in schizophrenia: relationships to function","volume":"14","author":"Sheffield","year":"2014","journal-title":"Cogn. Affect Behav. Neurosci."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib86","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/archpsyc.63.12.1325","article-title":"Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function","volume":"63","author":"Swerdlow","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib87","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10401230209149099","article-title":"Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome","volume":"14","author":"Tandon","year":"2002","journal-title":"Ann. Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib88","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in\u00a0vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib89","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/j.2051-5545.2008.tb00154.x","article-title":"Side effects of atypical antipsychotics: a brief overview","volume":"7","author":"Ucok","year":"2008","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib90","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/0269881109106925","article-title":"Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania","volume":"25","author":"Valvassori","year":"2011","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib91","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/schbul\/sbp132","article-title":"Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects","volume":"36","author":"van den Buuse","year":"2010","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib92","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1017\/S1461145708009371","article-title":"Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia","volume":"12","author":"Vigano","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib93","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3371\/CSRP.4.2.4","article-title":"Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development","volume":"4","author":"Wilson","year":"2010","journal-title":"Clin. Schizophr. Relat. Psychos."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib94","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/bph.12199","article-title":"Cannabidiol attenuates deficits of visuospatial associative memory induced by Delta(9) tetrahydrocannabinol","volume":"170","author":"Wright","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib95","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.2174\/138161212802884744","article-title":"The endocannabinoid system and schizophrenia: integration of evidence","volume":"18","author":"Zamberletti","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib96","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1476-5381.2009.00521.x","article-title":"Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors","volume":"159","author":"Zanelati","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib97","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF02244189","article-title":"Effects of cannabidiol in animal models predictive of antipsychotic activity","volume":"104","author":"Zuardi","year":"1991","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib98","first-page":"485","article-title":"Antipsychotic effect of cannabidiol","volume":"56","author":"Zuardi","year":"1995","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.jpsychires.2016.05.013_bib99","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/0269881106060967","article-title":"Cannabidiol monotherapy for treatment-resistant schizophrenia","volume":"20","author":"Zuardi","year":"2006","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib100","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/0269881108096519","article-title":"Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease","volume":"23","author":"Zuardi","year":"2009","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2016.05.013_bib101","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.2174\/138161212802884681","article-title":"A\u00a0critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation","volume":"18","author":"Zuardi","year":"2012","journal-title":"Curr. Pharm. Des."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395616301042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395616301042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T21:43:13Z","timestamp":1617572593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395616301042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":101,"alternative-id":["S0022395616301042"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2016.05.013","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Could cannabidiol be used as an alternative to antipsychotics?","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2016.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}